Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas

Cancer Gene Therapy

Volumn 22, Issue 6, 2015, Pages 302-311

  Choi, S A ^a   Lee, Y E ^a,b   Kwak, P A ^a   Lee, J Y ^a   Kim, S S ^b   Lee, S J ^b   Phi, J H ^a   Wang, K C ^a   Song, J ^c   Song, S H ^d   Joo, K M ^b,e   Kim, S K ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOTRANSPLANTATION; BRAIN STEM TUMOR; CANCER GENE THERAPY; CELL CULTURE; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ENGINEERING; GLIOMA; GLIOMA CELL LINE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL GENE THERAPY; SUBCUTANEOUS FAT; ANIMAL; BRAIN STEM NEOPLASMS; CYTOLOGY; DRUG SCREENING; GENE THERAPY; GENETICS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; TRANSGENE; TUMOR CELL LINE;

MUS;

ADIPOSE TISSUE; ANIMALS; BRAIN STEM NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; GLIOMA; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84931560997     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.25     Document Type: Article

References (52)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Jennings MT, Freeman ML, Murray MJ. Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J Neuro-Oncology 1996; 28: 207-222.
3. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neuro-Oncology 2008; 88: 245-250.
4. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-316.
5. Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 2005; 54: 132-141.
6. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neuro-Oncology 2007; 83: 241-247.
7. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
8. Safford KM, Rice HE. Stem cell therapy for neurologic disorders: therapeutic potential of adipose-derived stem cells. Curr Drug Targets 2005; 6: 57-62.
9. Choi SA, Lee JY, Wang KC, Phi JH, Song SH, Song J et al. Human adipose tissuederived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer 2012; 48: 129-137.
10. Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro-Oncology 2011; 13: 61-69.
11. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11: 1155-1164.
12. Danks MK, Yoon KJ, Bush RA, Remack JS, Wierdl M, Tsurkan L et al. Tumortargeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67: 22-25.
13. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia histochemica et cytobiologica/Pol Acad Sci Pol Histochem Cytochem Soc 2006; 44: 215-230.
14. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori H et al. Human adipose-derived stem cells: potential clinical applications in surgery. Surg Today 2011; 41: 18-23.
15. Szegezdi E, O'Reilly A, Davy Y, Vawda R, Taylor DL, Murphy M et al. Stem cells are resistant to TRAIL receptor-mediated apoptosis. J Cell Mol Med 2009; 13: 4409-4414.
16. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E et al. Adiposederived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010; 70: 3718-3729.
17. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005; 12: 585-598.
18. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro-Oncology 2009; 11: 80-91.
19. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662-664.
20. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52: 1103-1111.
21. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191.
22. Aboody KS, Najbauer J, Schmidt NO, Yang W, Wu JK, Zhuge Y et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-Oncology 2006; 8: 119-126.
23. Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998; 58: 2646-2651.
24. Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG, Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003; 13: 539-553.
25. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853.
26. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
27. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002; 4: 312-323.
28. Griffith TS, Stokes B, Kucaba TA, Earel JK Jr., VanOosten RL, Brincks EL et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9-19.
29. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998; 427: 124-128.
30. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010; 70: 1101-1110.
31. Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004; 64: 3236-3242.
32. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviralmediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886-2894.
33. Caretti V, Zondervan I, Meijer DH, Idema S, Vos W, Hamans B et al. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model. Brain Pathol 2011; 21: 441-451.
34. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162: 2597-2605.
35. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat Rev 2009; 35: 280-288.
36. Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T et al. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 2006; 13: 203-214.
37. Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro-Oncology 2010; 12: 687-700.
38. Aoki Y, Hashizume R, Ozawa T, Banerjee A, Prados M, James CD et al. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing. J Neuro-Oncology 2012; 108: 29-35.
39. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008; 270: 191-201.
40. Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006; 12: 5550-5556.
41. Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004; 24: 159-171.
42. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissuederived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-6313.
43. Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009; 15: 4925-4934.
44. Gutova M, Najbauer J, Chen MY, Potter PM, Kim SU, Aboody KS. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme. Curr Stem Cell Res Ther 2010; 5: 273-276.
45. Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr Stem Cell Res Ther 2009; 4: 44-49.
46. Niu J, Xing C, Yan C, Liu H, Cui Y, Peng H et al. Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma. Tumour Biol 2013; 34: 3731-3741.
47. Lee JY, Lee DH, Kim HA, Choi SA, Lee HJ, Park CK et al. Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures. J Neuro-Oncology 2014; 116: 49-57.
48. Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999; 5: 917-924.
49. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 2004; 23: 1283-1290.
50. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. International journal of cancer. J Int Cancer 2009; 124: 2505-2511.
51. Metz MZ, Gutova M, Lacey SF, Abramyants Y, Vo T, Gilchrist M et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Transl Med 2013; 2: 983-992.
52. Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X et al. hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Mol Ther 2011; 19: 1161-1169.